BiogenHAM:IDP +4.05%74 Quick Ratio is 2.41 as of Mar. 2026, which is 29% above its 10-year median of 1.87. GuruFocus rates HAM:IDP with a GF Score™ of 74/100 and a GF Value™ of €166.45 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 997 Drug Manufacturers companies, Biogen ranks better than 69.81% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Biogen's quick ratio for the quarter that ended in Mar. 2026 was 2.41.
Biogen has a quick ratio of 2.41. It generally indicates good short-term financial strength.
The historical rank and industry rank for Biogen's Quick Ratio or its related term are showing as below:
HAM:IDP'
s Quick Ratio Range Over the Past 10 Years
Min: 0.8 Med: 1.87 Max: 2.95
Current: 2.41
During the past 13 years, Biogen's highest Quick Ratio was 2.95. The lowest was 0.80. And the median was 1.87.
HAM:IDP's Quick Ratio is ranked better than 69.81% of 997
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs HAM:IDP: 2.41
Biogen (HAM:IDP) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Biogen Quick Ratio Related Terms
Biogen Quick Ratio Historical Data
* Premium members only.
The historical data trend for Biogen's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:IDP vs OGN, AMRN, SCLX: Quick Ratio Comparison
For the Drug Manufacturers - General subindustry, Biogen's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogen Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biogen's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Biogen's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Biogen's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogen (HAM:IDP) has a Quick Ratio of 2.41 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Biogen and its competitors. This is 29% above median its historical median of 1.87. Over the past decade, Biogen's Quick Ratio has ranged from 0.80 to 2.95. According to the industry distribution chart, Biogen ranks #301 out of 997 companies in the Drug Manufacturers industry, placing it in the top 30.2%.
Is Biogen's Quick Ratio too high?
Biogen's current Quick Ratio of 2.41 is 29% above median its 10-year median of 1.87. Over the past 10 years, this metric has ranged from a low of 0.80 to a high of 2.95. The Drug Manufacturers industry median Quick Ratio is 1.45. Biogen's value of 2.41 is 66.2% above this industry median. Based on the distribution chart, Biogen ranks #301 out of 997 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Biogen has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biogen's Quick Ratio compare to OGN and AMRN?
According to the Drug Manufacturers industry distribution chart, Biogen ranks #301 out of 997 companies for Quick Ratio. This puts Biogen in the upper half of its industry. The industry median Quick Ratio is 1.45. Biogen's value of 2.41 is 66.2% above this benchmark. Historically, Biogen's own Quick Ratio has ranged from 0.80 to 2.95 over the past decade. While the company's 10-year median is 1.87 vs. the industry median of 1.45, Biogen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biogen's current Quick Ratio of 2.41 is 66.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Biogen and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogen's current Quick Ratio is 2.41, which is 29% above median its own 10-year median of 1.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Based on GuruFocus' analysis, Biogen (HAM:IDP) is currently considered Modestly Overvalued. The stock's GF Value™ is €166.45, compared to a current price of €187.44 — trading 12.6% above its estimated fair value. The current Quick Ratio is 2.41, which is 29% above median its 10-year median of 1.87 and 66.2% above the Drug Manufacturers industry median of 1.45. Biogen's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Biogen (HAM:IDP), the current Quick Ratio is 2.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogen (HAM:IDP) Overvalued in 2026?
Based on GuruFocus' analysis, Biogen stock appears to be overvalued.
The current stock price of €187.44 is trading 12.6% above its estimated GF Value™ of €166.45.
GuruFocus considers Biogen to be Modestly Overvalued.
Key valuation signals for HAM:IDP:
Quick Ratio: 2.41 (29% above median its 10-year median of 1.87)
GF Value™: €166.45 vs. price of €187.44 (12.6% above fair value)
Industry Position: 66.2% above the Drug Manufacturers median (#301 of 997)
No single metric tells the full story. See the HAM:IDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
74GF Score
Get the complete analysis for HAM:IDP
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:IDP has been successfully added to your 
